Biogen Released Phase 2 Results for Lupus Treatment
The company shared 52-week data from its AMETHYST study evaluating the efficacy of litifilimab in patients.
Updated on Oct. 13, 2026 in Arthritis
Live Poll
Should patients with persistent skin inflammation seek specialist reassessment before waiting for current treatments to work?
Biogen has released 52-week data from the phase 2 AMETHYST study, which tested the drug litifilimab in 93 adults with active cutaneous lupus erythematosus. The treatment showed improvement in skin clarity among participants who were previously refractory or intolerant to antimalarial therapies.
Why it matters
Active cutaneous lupus erythematosus can lead to irreversible scarring and significant pigmentary changes if the condition is not successfully controlled. Litifilimab aims to mitigate these effects by targeting blood dendritic cell antigen 2 on plasmacytoid dendritic cells.
In the AMETHYST study of 93 adults, 27.2% of participants receiving litifilimab achieved a CLA-IGA-R erythema score of 0 or 1 at week 52. Serious adverse events occurred in 6.8% of the litifilimab group and 2.9% of the placebo group during the first 24 weeks.
The players
Biogen
Biogen is a global biotechnology company focused on developing therapies for neurological and immunological diseases.
The details
Participants who switched from placebo to litifilimab at week 24 demonstrated clinical improvement within 4 weeks of starting the active treatment. All study participants were placed on active treatment after the initial 24-week period, with 3.4% reporting serious adverse events during the extension phase.
Timeline
March 2026 was the initial timeframe for Biogen's reporting of phase 2 trial data.
October 2, 2026, marked the release of the 52-week AMETHYST study findings.
The first half of 2027 is when phase 3 trial results are expected.
Health Landscape
The development of litifilimab fits into a broader shift in immunology toward targeting plasmacytoid dendritic cells to treat autoimmune conditions. This approach marks a departure from traditional antimalarial treatments by offering a more targeted biological intervention for systemic and cutaneous lupus patients.
The study offers hope for patients who have failed to respond to current standard antimalarial treatments for cutaneous lupus. While these findings show promise, the drug is still in clinical testing and is not yet available as a prescribed treatment for the general public.
The takeaway
Patients who struggle with skin symptoms of lupus may soon have new targeted options as clinical research progresses. Those managing chronic conditions should consult their healthcare provider to discuss how upcoming drug developments might influence their future care plans.
What happens next
Biogen expects to report results from its phase 3 trial in the first half of 2027.
Further reading
Learn more about advancements in managing Arthritis and related autoimmune conditions.
More information
Review the full Biogen phase 2 study results to see the technical trial breakdown.
Live Poll
Should patients with persistent skin inflammation seek specialist reassessment before waiting for current treatments to work?
